Speaking of SurgOnc™ is a podcast brought to you by the Annals of Surgical Oncology (ASO) and the Society of Surgical Oncology (SSO).
The series is hosted by ASO Deputy Editor Dr. Frederick L. (Rick) Greene, who will expand upon ideas from articles published in the Annals of Surgical Oncology.
Once a month, Dr. Greene will interview authors and leading experts in surgical oncology. Speaking of SurgOnc™ episodes will be available on this page and wherever you listen to your favorite podcasts, including Apple Podcasts, Spotify, Stitcher. iHeartRadio and TuneIn.
Episode 6: Modified Frailty Index Predicts Morbidity and Mortality After Pancreaticoduodenectomy
November 12, 2019
Dr. Rick Greene and Dr. Clancy Clark discuss use of a modified frailty index as a predictor in pancreaticoduodenectomy, its association with postoperative morbidity and mortality, and how it can aid in preoperative risk stratification.
Dr. Clark is author of, “Modified Frailty Index Predicts Morbidity and Mortality After Pancreaticoduodenectomy.”
Dr. Clark is an Assistant Professor, Department of Surgery, at Wake Forest Baptist Health in Winston-Salem, NC. He is a hepatobiliary and pancreatic surgeon specializing in pancreatic cancer.
Episode 5: Impact of Chemoradiation-to-Surgery Interval on Pathological Complete Response and Short- and Long-Term Overall Survival in Esophageal Cancer Patients
October 7, 2019
Dr. Rick Greene and Dr. Basem Azab discuss the relationship of the interval between neoadjuvant chemoradiation-to-surgery in the treatment of esophageal cancer, and associated pathological complete response rate and overall survival rate.
Dr. Azab is author of the Annals of Surgical Oncology article “Impact of Chemoradiation-to-Surgery Interval on Pathological Complete Response and Short- and Long-Term Overall Survival in Esophageal Cancer Patients.”
Dr. Azab is a surgical oncology specialist at Sentara Healthcare, Newport News, VA. His clinical expertise includes but is not limited to Esophageal Cancer, Endocrine Tumors, Gastrointestinal Oncology, Hepatobiliary Tumors.
Episode 4: The 8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers
September 9, 2019
Dr. Rick Greene and Dr. Tim Pawlik will discuss the 8th edition of the TNM staging system for pancreas and hepatobiliary cancers, which affirms that the anatomic extent of disease remains the strongest predictor of outcome in hepatobiliary cancers.
Dr. Pawlik is ASO Deputy Editor and Editorial Board Section Editor, Hepatobiliary Tumors. He is co-author with Yun Shin Chun and Jean-Nicolas Vauthey of the ASO TNM staging editorial, “8th Edition of the AJCC Cancer Staging Manual: Pancreas and Hepatobiliary Cancers.”
Dr. Pawlik’s primary clinical interests include alimentary tract surgery, with a special interest in hepatic, pancreatic, and biliary diseases. He is a member of the Johns Hopkins’ Miller-Coulson Academy of Clinical Excellence, in recognition of consummate clinical excellence in his field.
Dr. Pawlik is Chair of The Ohio State University Wexner Medical Center’s Department of Surgery, as well as The Urban Meyer III and Shelley Meyer Chair for Cancer Research.
Episode 3: The 8th Edition of the AJCC Cancer Staging Manual: Breast Cancer
August 9, 2019
Dr. Greene and Dr. Stephen Edge will discuss the TNM staging system and its relevance to breast cancer management.
Dr. Edge was Editor-in-Chief of the 7th Edition of the AJCC Cancer Staging Manual published in 2009 and co-author with Armando E. Giuliano and Gabriel N. Hortobagyi of the ASO editorial, “Eighth Edition of the AJCC Cancer Staging Manual: Breast Cancer”
Dr. Edge is the Vice President for Healthcare Outcomes Policy and Professor of Oncology at the Roswell Park Cancer Institute.
Dr. Edge also serves as Immediate Past Chair of the Commission on Cancer, on the Cancer Support Community Policy Institute of the National Advisory Board.
Episode 2: Melanoma Staging: American Joint Committee on Cancer 8th Edition and Beyond
July 8, 2019
Dr. Greene and Dr. Jeffrey E. Gershenwald discuss the 8th edition of the TNM staging system for melanoma, and its use for communication between physicians and their patients as well as its impact on decision-making and prognostic assessment.
Dr. Gershenwald is co-author with Richard A. Scolyer, MD of the ASO TNM staging editorial, “Melanoma Staging: American Joint Committee on Cancer (AJCC) 8th Edition and Beyond.”
Dr. Gershenwald is a surgical oncologist-investigator in melanoma, with a research focus on integrating clinical, pathological, molecular and immune factors to improve melanoma staging and to develop clinical tools to improve clinical decision-making for patients with melanoma.
Dr. Gershenwald is the Dr. John M. Skibber Professor of Surgery, Department of Surgical Oncology, and Medical Director, Melanoma and Skin Center, The University of Texas MD Anderson Cancer Center, Houston, and Chair, American Joint Committee on Cancer (AJCC) Melanoma Expert Panel.
Episode 1: The 8th Edition of TNM: Implications for the Surgical Oncologist
June 11, 2019
In the inaugural episode of the Speaking of SurgOnc™ podcast Dr. Rick Greene and Dr. David R. Byrd discuss the 8th edition of the TNM staging system, which through its advances supports the concept of a team approach to cancer staging by clinical oncologists including cancer registrars, pathologists, and radiologists.
Dr. Byrd is co-author with Dr. Greene of the ASO TNM staging editorial, “The 8th Edition of TNM: Implications for the Surgical Oncologist.”
Dr. Byrd is the current Chair of the American Joint Committee on Cancer (AJCC) and his clinical expertise includes surgical oncology, endocrine neoplasms (thyroid, parathyroid, adrenal), breast cancer, melanoma, and Merkel cell carcinoma.
Dr. Byrd is Professor of Surgery and the Section Chief of Surgical Oncology at the University of Washington.